JPWO2019169328A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2019169328A5 JPWO2019169328A5 JP2020568945A JP2020568945A JPWO2019169328A5 JP WO2019169328 A5 JPWO2019169328 A5 JP WO2019169328A5 JP 2020568945 A JP2020568945 A JP 2020568945A JP 2020568945 A JP2020568945 A JP 2020568945A JP WO2019169328 A5 JPWO2019169328 A5 JP WO2019169328A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- composition
- protein
- amino acid
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims 8
- 150000001875 compounds Chemical class 0.000 claims 7
- 125000003275 alpha amino acid group Chemical group 0.000 claims 6
- 102000004169 proteins and genes Human genes 0.000 claims 6
- 108090000623 proteins and genes Proteins 0.000 claims 6
- 206010028980 Neoplasm Diseases 0.000 claims 4
- 201000011510 cancer Diseases 0.000 claims 4
- 241000701806 Human papillomavirus Species 0.000 claims 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 2
- 150000002632 lipids Chemical class 0.000 claims 2
- 239000002773 nucleotide Substances 0.000 claims 2
- 125000003729 nucleotide group Chemical group 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims 2
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 claims 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-N Thiophosphoric acid Chemical class OP(O)(S)=O RYYWUUFWQRZTIU-UHFFFAOYSA-N 0.000 claims 1
- 238000002512 chemotherapy Methods 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 201000000459 head and neck squamous cell carcinoma Diseases 0.000 claims 1
- 239000002777 nucleoside Substances 0.000 claims 1
- 125000003835 nucleoside group Chemical group 0.000 claims 1
- 229910052697 platinum Inorganic materials 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023222587A JP2024045151A (ja) | 2018-03-02 | 2023-12-28 | Ｃｐｇアンフィフィル及びその使用 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862637824P | 2018-03-02 | 2018-03-02 | |
| US62/637,824 | 2018-03-02 | ||
| PCT/US2019/020398 WO2019169328A1 (en) | 2018-03-02 | 2019-03-01 | Cpg amphiphiles and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023222587A Division JP2024045151A (ja) | 2018-03-02 | 2023-12-28 | Ｃｐｇアンフィフィル及びその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021516991A JP2021516991A (ja) | 2021-07-15 |
| JP2021516991A5 JP2021516991A5 (https=) | 2022-03-09 |
| JPWO2019169328A5 true JPWO2019169328A5 (https=) | 2022-03-09 |
Family
ID=67805576
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020568945A Pending JP2021516991A (ja) | 2018-03-02 | 2019-03-01 | Ｃｐｇアンフィフィル及びその使用 |
| JP2023222587A Pending JP2024045151A (ja) | 2018-03-02 | 2023-12-28 | Ｃｐｇアンフィフィル及びその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023222587A Pending JP2024045151A (ja) | 2018-03-02 | 2023-12-28 | Ｃｐｇアンフィフィル及びその使用 |
Country Status (20)
| Country | Link |
|---|---|
| US (3) | US12247052B2 (https=) |
| EP (1) | EP3758712B1 (https=) |
| JP (2) | JP2021516991A (https=) |
| KR (2) | KR20250111403A (https=) |
| CN (2) | CN120249290A (https=) |
| AU (1) | AU2019227988B2 (https=) |
| BR (1) | BR112020017778A2 (https=) |
| CA (1) | CA3092693A1 (https=) |
| DK (1) | DK3758712T3 (https=) |
| ES (1) | ES3035198T3 (https=) |
| IL (1) | IL277101B2 (https=) |
| MA (1) | MA52434A (https=) |
| MX (1) | MX2020009150A (https=) |
| MY (1) | MY209484A (https=) |
| PL (1) | PL3758712T3 (https=) |
| PT (1) | PT3758712T (https=) |
| SA (1) | SA520420065B1 (https=) |
| SG (1) | SG11202008432XA (https=) |
| UA (1) | UA128863C2 (https=) |
| WO (1) | WO2019169328A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11696954B2 (en) | 2017-04-28 | 2023-07-11 | Exicure Operating Company | Synthesis of spherical nucleic acids using lipophilic moieties |
| WO2018209270A1 (en) | 2017-05-11 | 2018-11-15 | Northwestern University | Adoptive cell therapy using spherical nucleic acids (snas) |
| BR112020017645A2 (pt) | 2018-03-02 | 2020-12-29 | Elicio Therapeutics Inc. | Compostos que incluem uma sequência kras mutante e um lipídio e usos dos mesmos |
| CN116507344A (zh) * | 2020-06-26 | 2023-07-28 | 伊莱西奥治疗有限公司 | 用于诱导针对冠状病毒的免疫应答的组合物和方法 |
| AU2021294342A1 (en) * | 2020-06-26 | 2023-02-23 | Elicio Therapeutics, Inc. | Compositions and methods for inducing an immune response against coronavirus |
| US20250134992A1 (en) * | 2021-08-16 | 2025-05-01 | Elicio Therapeutics, Inc. | Compositions containing polynucleotide amphiphiles and methods of use thereof |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6168778B1 (en) * | 1990-06-11 | 2001-01-02 | Nexstar Pharmaceuticals, Inc. | Vascular endothelial growth factor (VEGF) Nucleic Acid Ligand Complexes |
| AU2001268427B2 (en) | 2000-06-16 | 2007-03-29 | Glaxosmithkline Intellectual Property Limited | Antibodies that immunospecifically bind to blys |
| US8771702B2 (en) * | 2001-03-26 | 2014-07-08 | The Trustees Of The University Of Pennsylvania | Non-hemolytic LLO fusion proteins and methods of utilizing same |
| WO2005001116A1 (ja) * | 2003-06-17 | 2005-01-06 | Meiji Dairies Corporation | Toll様レセプター強制発現細胞の利用 |
| US9090673B2 (en) * | 2003-12-12 | 2015-07-28 | City Of Hope | Synthetic conjugate of CpG DNA and T-help/CTL peptide |
| CA2574090A1 (en) * | 2004-07-18 | 2006-12-21 | Coley Pharmaceutical Group, Ltd. | Methods and compositions for inducing innate immune responses |
| NZ575437A (en) | 2006-09-27 | 2012-02-24 | Coley Pharm Gmbh | Cpg oligonucleotide analogs containing hydrophobic t analogs with enhanced immunostimulatory activity |
| EP2155889A4 (en) * | 2007-05-25 | 2010-06-16 | Centocor Ortho Biotech Inc | TOLL RECEPTOR 3 MODULATORS AND USES THEREOF |
| US20120087949A1 (en) * | 2008-12-19 | 2012-04-12 | University Of Florida Research Foundation, Inc. | Oligonucleotide micelles |
| ES2731343T3 (es) | 2009-05-19 | 2019-11-15 | Univ Miami | Composiciones, kits y métodos para presentación de antígenos in vitro, evaluación de eficacia de vacunas y evaluación de la inmunotoxicidad de productos biológicos y fármacos |
| WO2011036557A1 (en) * | 2009-09-22 | 2011-03-31 | The University Of British Columbia | Compositions and methods for enhancing cellular uptake and intracellular delivery of lipid particles |
| AU2011227714B2 (en) | 2010-03-19 | 2014-09-04 | Takeda Pharmaceutical Company Limited | TFPI inhibitors and methods of use |
| KR20140005998A (ko) * | 2011-01-24 | 2014-01-15 | 안테리오스, 인코퍼레이티드 | 나노입자 조성물, 이의 제형, 및 그의 용도 |
| EP4427814A3 (en) | 2011-05-25 | 2024-11-20 | Camurus AB | Controlled release peptide formulations |
| CA2849705A1 (en) | 2011-09-23 | 2013-03-28 | Technophage, Investigacao E Desenvolvimento Em Biotecnologia, Sa | Modified albumin-binding domains and uses thereof to improve pharmacokinetics |
| EP2908853B1 (en) | 2012-10-21 | 2018-12-05 | University Of Rochester | Thy1 (cd90) as a therapy to control adipose tissue accumulation |
| KR102109188B1 (ko) | 2013-04-01 | 2020-05-11 | 삼성전자주식회사 | 양이온성 지질을 포함하는 온도민감성 리포좀 및 그의 용도 |
| AR095882A1 (es) * | 2013-04-22 | 2015-11-18 | Hoffmann La Roche | Terapia de combinación de anticuerpos contra csf-1r humano con un agonista de tlr9 |
| KR102100289B1 (ko) * | 2013-10-24 | 2020-04-13 | 주식회사 다이셀 | 은 나노 입자 함유 분산액의 제조 방법 및 은 나노 입자 함유 분산액 |
| JP2017532373A (ja) * | 2014-09-11 | 2017-11-02 | ヴェダントラ ファーマシューティカルズ，インコーポレーテッド | マルチラメラ脂質ベシクル組成物及び使用方法 |
| US10940201B2 (en) * | 2015-09-30 | 2021-03-09 | Shionogi & Co., Ltd. | Nucleic acid derivative having immunostimulatory activity |
| JP7197481B2 (ja) | 2016-11-30 | 2022-12-27 | アドバクシス， インコーポレイテッド | 反復性がん突然変異を標的とする免疫原性組成物およびその使用の方法 |
| CA3054172A1 (en) * | 2017-02-23 | 2018-08-30 | Alpha-O Peptides Ag | Self-assembling protein nanoparticles encapsulating immunostimulatory nucleid acids |
| BR112020017645A2 (pt) * | 2018-03-02 | 2020-12-29 | Elicio Therapeutics Inc. | Compostos que incluem uma sequência kras mutante e um lipídio e usos dos mesmos |
-
2019
- 2019-03-01 DK DK19761384.7T patent/DK3758712T3/da active
- 2019-03-01 JP JP2020568945A patent/JP2021516991A/ja active Pending
- 2019-03-01 CN CN202510413325.0A patent/CN120249290A/zh active Pending
- 2019-03-01 UA UAA202006353A patent/UA128863C2/uk unknown
- 2019-03-01 IL IL277101A patent/IL277101B2/en unknown
- 2019-03-01 CN CN201980028828.9A patent/CN112203663A/zh active Pending
- 2019-03-01 EP EP19761384.7A patent/EP3758712B1/en active Active
- 2019-03-01 WO PCT/US2019/020398 patent/WO2019169328A1/en not_active Ceased
- 2019-03-01 US US16/977,185 patent/US12247052B2/en active Active
- 2019-03-01 MY MYPI2020004499A patent/MY209484A/en unknown
- 2019-03-01 MX MX2020009150A patent/MX2020009150A/es unknown
- 2019-03-01 CA CA3092693A patent/CA3092693A1/en active Pending
- 2019-03-01 ES ES19761384T patent/ES3035198T3/es active Active
- 2019-03-01 PL PL19761384.7T patent/PL3758712T3/pl unknown
- 2019-03-01 AU AU2019227988A patent/AU2019227988B2/en active Active
- 2019-03-01 KR KR1020257023614A patent/KR20250111403A/ko active Pending
- 2019-03-01 SG SG11202008432XA patent/SG11202008432XA/en unknown
- 2019-03-01 KR KR1020207028281A patent/KR102837422B1/ko active Active
- 2019-03-01 BR BR112020017778-4A patent/BR112020017778A2/pt unknown
- 2019-03-01 MA MA052434A patent/MA52434A/fr unknown
- 2019-03-01 PT PT197613847T patent/PT3758712T/pt unknown
-
2020
- 2020-08-31 SA SA520420065A patent/SA520420065B1/ar unknown
-
2023
- 2023-12-28 JP JP2023222587A patent/JP2024045151A/ja active Pending
-
2025
- 2025-01-31 US US19/042,771 patent/US20250171507A1/en not_active Abandoned
- 2025-09-19 US US19/333,784 patent/US20260015390A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021516991A5 (https=) | ||
| JP7504464B2 (ja) | 核酸ワクチン | |
| ES3005233T3 (en) | Modified nucleosides, nucleotides, and nucleic acids, and uses thereof | |
| FI86194B (fi) | Foerfarandena foer framstaellning av polypeptidhomologer av tumoernekrosisfaktorer med stor utbyte. | |
| JP2021517471A5 (https=) | ||
| CN110643609B (zh) | 一种核苷类似物药物分子构建的药物适配体及其制备方法和应用 | |
| JP2024045151A (ja) | Ｃｐｇアンフィフィル及びその使用 | |
| CN112226413B (zh) | 基于SARS-CoV-2 S蛋白RBD区域的靶向性外泌体及其制备方法 | |
| RU97112396A (ru) | Химические соединения | |
| JPWO2019169328A5 (https=) | ||
| WO2021121173A1 (zh) | 基于结合N-乙酰半乳糖胺多肽的mRNA靶向分子及其制备方法 | |
| US8957186B2 (en) | Recombinant protein for intracellular delivery of siRNA and composition comprising the same | |
| CN109666064B (zh) | SALL4-RBBp4复合物阻断多肽和衍生抗肿瘤多肽及其应用 | |
| TWI293958B (en) | Functional derivatives of the long pentraxin ptx3 for the preparation of an autologous vaccine for the treatment of tumours | |
| CN101289653A (zh) | 尼古丁处理后树突状细胞用于预防和治疗肿瘤 | |
| CN115916975A (zh) | 靶向mitf基因的核酸分子及其用途 | |
| JPWO2023004437A5 (https=) | ||
| CN102675428A (zh) | 肝靶向穿膜抗病毒融合多肽及其编码基因与应用 | |
| CN111321159A (zh) | 用于免疫调节的嵌合核酸分子及其应用 | |
| CN121003688A (zh) | 一种dsRNA与干扰素的联合治疗 | |
| CN101041066B (zh) | 重组鲨肝刺激物质类似物用于治疗慢性肝脏疾病的用途 | |
| CN101642462B (zh) | 一种肿瘤抑制剂nrn1sr42 | |
| WO2025092908A1 (zh) | 治疗HPV感染相关疾病的mRNA疫苗 | |
| CN117531016A (zh) | NRP1和TGF-βR抑制剂组合在制备肾损伤治疗药物中的应用 | |
| CN116983391A (zh) | 一种增强免疫力和防治感染性疾病及其并发症的治疗方法 |